These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1429 related items for PubMed ID: 32421226

  • 1. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R, Kobayashi K, Usuki J, Yomota M, Nishitsuji M, Shimokawa T, Ando M, Hino M, Hagiwara K, Miyanaga A, Seike M, Kubota K, Gemma A, North East Japan Study group.
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K, North East Japan Study Group.
    Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
    [Abstract] [Full Text] [Related]

  • 3. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
    Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T.
    Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
    [Abstract] [Full Text] [Related]

  • 4. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
    Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T.
    Med Oncol; 2013 Aug; 30(3):676. PubMed ID: 23925664
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
    Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A.
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H, Meng Q, Li M, Shi L, Tang J, Liu Z.
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [Abstract] [Full Text] [Related]

  • 7. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T.
    Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
    [Abstract] [Full Text] [Related]

  • 8. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
    Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K.
    BMC Cancer; 2016 May 12; 16():306. PubMed ID: 27177035
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.
    Indian J Cancer; 2014 Mar 12; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [Abstract] [Full Text] [Related]

  • 10. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Shiraishi Y, Kishimoto J, Tanaka K, Sugawara S, Daga H, Hirano K, Azuma K, Hataji O, Hayashi H, Tachihara M, Mitsudomi T, Seto T, Nakagawa K, Yamamoto N, Okamoto I.
    Clin Lung Cancer; 2020 Sep 12; 21(5):472-476. PubMed ID: 32381420
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group.
    Int J Clin Oncol; 2018 Dec 12; 23(6):1060-1069. PubMed ID: 30027464
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
    Takemoto S, Fukuda M, Yamaguchi H, Ikeda T, Akagi K, Tomono H, Umeyama Y, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Kitazaki T, Nakatomi K, Nagashima S, Fukuda M, Kinoshita A, Soda H, Mukae H.
    Thorac Cancer; 2020 Feb 12; 11(2):389-393. PubMed ID: 31851428
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol; 2009 Jul 10; 27(20):3284-9. PubMed ID: 19433684
    [Abstract] [Full Text] [Related]

  • 14. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
    Shibata Y, Kobayashi N, Sato T, Nakashima K, Kaneko T.
    Thorac Cancer; 2020 May 10; 11(5):1258-1264. PubMed ID: 32163231
    [Abstract] [Full Text] [Related]

  • 15. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H.
    Oncol Rep; 2013 Jun 10; 29(6):2332-40. PubMed ID: 23525453
    [Abstract] [Full Text] [Related]

  • 16. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Gridelli C, Rossi A, Ciardiello F, De Marinis F, Crinò L, Morabito A, Morgillo F, Montanino A, Daniele G, Piccirillo MC, Normanno N, Gallo C, Perrone F.
    Clin Lung Cancer; 2016 Sep 10; 17(5):461-465. PubMed ID: 27209164
    [Abstract] [Full Text] [Related]

  • 17. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M.
    BMC Cancer; 2018 Dec 10; 18(1):1231. PubMed ID: 30526545
    [Abstract] [Full Text] [Related]

  • 18. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH.
    Clin Lung Cancer; 2020 Nov 10; 21(6):520-526. PubMed ID: 32807654
    [Abstract] [Full Text] [Related]

  • 19. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
    Weiss JM, Villaruz LC, O'Brien J, Ivanova A, Lee C, Olson JG, Pollack G, Gorman R, Socinski MA, Stinchombe TE.
    Clin Lung Cancer; 2016 Mar 10; 17(2):128-32. PubMed ID: 26774201
    [Abstract] [Full Text] [Related]

  • 20. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D.
    Lancet Oncol; 2020 Mar 10; 21(3):387-397. PubMed ID: 32035514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.